Sonic Healthcare Limited (ASX: SHL)

Market Cap	12.75B
Revenue (ttm)	8.21B
Net Income (ttm)	504.94M
Shares Out	473.43M
EPS (ttm)	1.07
PE Ratio	24.82
Forward PE	17.92
Dividend	1.05 (3.95%)
Ex-Dividend Date	Mar 1, 2024

Volume	960,484
Open	26.70
Previous Close	26.62
Day's Range	26.56 - 26.96
52-Week Range	25.72 - 36.40
Beta	0.49
Analysts	n/a
Price Target	30.86 (+16.19%)
Earnings Date	Feb 20, 2024

About Sonic Healthcare

Sonic Healthcare Limited offers medical diagnostic services to medical practitioners, hospitals, community health services, and their collective patients. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT...

• Industry: Diagnostics & Research
• Sector: Healthcare
• CEO: Dr. Colin Stephen Goldschmidt F.A.C.I.D., F.A.I.C.D., F.R.C.P.A., M.B.B.Ch.
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SHL

Financial Performance

In 2023, SHL's revenue was 7.96 billion, a decrease of -14.42% compared to the previous year's 9.31 billion. Earnings were 684.98 million, a decrease of -53.10%.